Development of an age-scalable 3D computational phantom in DICOM standard for late effects studies of childhood cancer survivors
- PMID: 34584772
- PMCID: PMC8475741
- DOI: 10.1088/2057-1976/ab97a3
Development of an age-scalable 3D computational phantom in DICOM standard for late effects studies of childhood cancer survivors
Abstract
Purpose: We previously developed an age-scalable 3D computational phantom that has been widely used for retrospective whole-body dose reconstructions of conventional two-dimensional historic radiation therapy (RT) treatments in late effects studies of childhood cancer survivors. This phantom is modeled in the FORTRAN programming language and is not readily applicable for dose reconstructions for survivors treated with contemporary RT whose treatment plans were designed using computed tomography images and complex treatment fields. The goal of this work was to adapt the current FORTRAN model of our age-scalable computational phantom into Digital Imaging and Communications in Medicine (DICOM) standard so that it can be used with any treatment planning system (TPS) to reconstruct contemporary RT. Additionally, we report a detailed description of the phantom's age-based scaling functions, information that was not previously published.
Method: We developed a Python script that adapts our phantom model from FORTRAN to DICOM. To validate the conversion, we compared geometric parameters for the phantom modeled in FORTRAN and DICOM scaled to ages 1 month, 6 months, 1, 2, 3, 5, 8, 10, 15, and 18 years. Specifically, we calculated the percent differences between the corner points and volume of each body region and the normalized mean square distance (NMSD) between each of the organs. In addition, we also calculated the percent difference between the heights of our DICOM age-scaled phantom and the heights (50th percentile) reported by the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) for male and female children of the same ages. Additionally, we calculated the difference between the organ masses for our DICOM phantom and the organ masses for two reference phantoms (from International Comission on Radiation Protection (ICRP) 89 and the University of Florida/National Cancer Institute reference hybrid voxel phantoms) for ages newborn, 1, 5, 10, 15 and adult. Lastly, we conducted a feasibility study using our DICOM phantom for organ dose calculations in a commercial TPS. Specifically, we simulated a 6 MV photon right-sided flank field RT plan for our DICOM phantom scaled to age 3.9 years; treatment field parameters and age were typical of a Wilms tumor RT treatment in the Childhood Cancer Survivor Study. For comparison, the same treatment was simulated using our in-house dose calculation system with our FORTRAN phantom. The percent differences (between FORTRAN and DICOM) in mean dose and percent of volume receiving dose ⩾5 Gy were calculated for two organs at risk, liver and pancreas.
Results: The percent differences in corner points and the volumes of head, neck, and trunk body regions between our phantom modeled in FORTRAN and DICOM agreed within 3%. For all of the ages, the NMSDs were negliglible with a maximum NMSD of 7.80 × 10-2 mm for occiptital lobe of 1 month. The heights of our age-scaled phantom agreed with WHO/CDC data within 7% from infant to adult, and within 2% agreement for ages 5 years and older. We observed that organ masses in our phantom are less than the organ masses for other reference phantoms. Dose calculations done with our in-house calculation system (with FORTRAN phantom) and commercial TPS (with DICOM phantom) agreed within 7%.
Conclusion: We successfully adapted our phantom model from the FORTRAN language to DICOM standard and validated its geometric consistency. We also demonstrated that our phantom model is representative of population height data for infant to adult, but that the organ masses are smaller than in other reference phantoms and need further refinement. Our age-scalable computational phantom modeled in DICOM standard can be scaled to any age at RT and used within a commercial TPS to retrospectively reconstruct doses from contemporary RT in childhood cancer survivors.
Keywords: computational phantoms; dose reconstruction; late effects; pediatric phantoms.
Figures







Similar articles
-
Body region-specific 3D age-scaling functions for scaling whole-body computed tomography anatomy for pediatric late effects studies.Biomed Phys Eng Express. 2022 Feb 1;8(2):10.1088/2057-1976/ac3f4e. doi: 10.1088/2057-1976/ac3f4e. Biomed Phys Eng Express. 2022. PMID: 34874300 Free PMC article.
-
Feasibility and accuracy of UF/NCI phantoms and Monte Carlo retrospective dosimetry in children treated on National Wilms Tumor Study protocols.Pediatr Blood Cancer. 2018 Dec;65(12):e27395. doi: 10.1002/pbc.27395. Epub 2018 Aug 12. Pediatr Blood Cancer. 2018. PMID: 30101560 Free PMC article.
-
Conversion of computational human phantoms into DICOM-RT for normal tissue dose assessment in radiotherapy patients.Phys Med Biol. 2019 Jul 5;64(13):13NT02. doi: 10.1088/1361-6560/ab2670. Phys Med Biol. 2019. PMID: 31158829 Free PMC article.
-
Liver Late Effects in Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review.Int J Radiat Oncol Biol Phys. 2024 Jun 1;119(2):575-587. doi: 10.1016/j.ijrobp.2023.06.002. Epub 2023 Jul 20. Int J Radiat Oncol Biol Phys. 2024. PMID: 37480885 Review.
-
Kidney Disease in Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review.Int J Radiat Oncol Biol Phys. 2024 Jun 1;119(2):560-574. doi: 10.1016/j.ijrobp.2023.02.040. Epub 2023 Jul 14. Int J Radiat Oncol Biol Phys. 2024. PMID: 37452796 Review.
Cited by
-
Validation and Comparison of Radiograph-Based Organ Dose Reconstruction Approaches for Wilms Tumor Radiation Treatment Plans.Adv Radiat Oncol. 2022 Jul 4;7(6):101015. doi: 10.1016/j.adro.2022.101015. eCollection 2022 Nov-Dec. Adv Radiat Oncol. 2022. PMID: 36060631 Free PMC article.
-
Body region-specific 3D age-scaling functions for scaling whole-body computed tomography anatomy for pediatric late effects studies.Biomed Phys Eng Express. 2022 Feb 1;8(2):10.1088/2057-1976/ac3f4e. doi: 10.1088/2057-1976/ac3f4e. Biomed Phys Eng Express. 2022. PMID: 34874300 Free PMC article.
-
Late-onset kidney failure in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.Eur J Cancer. 2021 Sep;155:216-226. doi: 10.1016/j.ejca.2021.06.050. Epub 2021 Aug 11. Eur J Cancer. 2021. PMID: 34391054 Free PMC article.
-
Development and validation of an age-scalable cardiac model with substructures for dosimetry in late-effects studies of childhood cancer survivors.Radiother Oncol. 2020 Dec;153:163-171. doi: 10.1016/j.radonc.2020.10.017. Epub 2020 Oct 17. Radiother Oncol. 2020. PMID: 33075392 Free PMC article.
-
Radiation therapy related cardiac disease risk in childhood cancer survivors: Updated dosimetry analysis from the Childhood Cancer Survivor Study.Radiother Oncol. 2021 Oct;163:199-208. doi: 10.1016/j.radonc.2021.08.012. Epub 2021 Aug 26. Radiother Oncol. 2021. PMID: 34454975 Free PMC article.
References
-
- Asdahl PH et al.2015The Adult Life After Childhood Cancer in Scandinavia (ALiCCS) study: design and characteristics Pediatr Blood Cancer 622204–10 - PubMed
-
- Centers for Disease Control and Prevention 2000National Center for Health Statistics. CDC Growth Charts (United States: National Center for Health Statistics; ) - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical